口腔粘膜鳞癌顺铂诱导化疗剂量与疗效关系的研究

目的 :探讨口腔粘膜鳞状细胞癌顺铂诱导化疗剂量与疗效的关系。方法 :总结 1986～ 2 0 0 0年 6月间行计划性高剂量 (10 0～ 12 0mg/m2 )顺铂诱导化疗的 99例治疗经验。以同期非常规剂量 (5 0mg/m2 )的 2 7例作对比研究。结果 :高剂量组和对比组的近期疗效分别为 85 .85 % (85 / 99)和 5 5 .5 5 % (15 / 2 7) ,经统计学处理有高度显著性差异 (P <0 .0 1) ;毒副反应 (肾、血液和胃肠毒性 )本组实验的对照观察中均无显著性差异 (P >0 .0 5 )。结论 :顺铂剂量和疗效之间呈正相关和正态剂量依赖关系 ,高剂量组的 10 0～ 12 0mg/m2 的剂量是合适和符合人体耐受的 ,毒副反应尚未影响到本疗法的临床应用     

口腔粘膜鳞癌顺铂诱导化疗剂量与疗效关系的研究

目的：探讨口腔粘膜鳞状细胞癌顺铂诱导化疗剂量与疗效的关系。方法：总结1986－2000年6月间行计划性高剂量（100－120mg/m^2)顺铂诱导化疗的99例治疗经验。以同期非常规剂量（50mg/m^2)的27例作对比研究。结果：高剂量组和对比组的近期疗效分别为85．85％（85／99）和55．55％（15／27）,经统计学处理有高度显著性差异（P＜0．01）;毒副反应（肾、血液和胃肠毒性）本组实验的对照观察中均无显著性差异（P＞0．05）。结论：顺铂剂量和疗效之间呈正相关和正态剂量依赖关系,高剂量组的100－120mg/m^2的剂量是合适和符合人体耐受的,毒副反应尚未影响到本疗法的临床应用。     

口腔癌靶向隐形顺铂聚乳酸纳米粒的急性毒性研究

目的：研究口腔癌靶向顺铂聚乳酸聚乙二醇纳米粒(CDDP—PLA—PEG—NP,或称隐形顺铂聚乳酸纳米)的急性毒性作用。方法：用不同剂量的CDDP—PLA—PEG—NP和顺铂(CDDP)行小鼠皮下和尾静脉注射,观察小鼠用药后的毒副反应,并计算半数致死量(LD_(50))。结果：CDDP—PLA—PEG—NP皮下和静脉注射的LD_(50)值分别为(28．87±2．02)mg/kg,(15．37±1．23)mg/kg,CDDP皮下和静脉注射的LD_(50)值分别为：(16．82±1．34) mg/kg,(10．62±0．77)mg/kg。结论：CDDP—PLA—PEG—NP对机体的毒副作用无论皮下或静脉注射均小于CDDP,证明CDDP的纳米剂型降低了CDDP药物的毒性作用,为以后的动物实验和临床实验提供了依据。     

尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶治疗晚期口腔癌的短期疗效观察

目的 观察尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶(DCF)治疗晚期口腔癌的短期疗效及不良反应.方法 9例晚期口腔癌患者采用尼妥珠单抗联合DCF化学治疗方案:尼妥珠单抗200 mg,每周1次,连用6个周期;多西他赛75 mg·m-2,第1天,静脉滴注;顺铂75 mg·m-2,第1天,静脉滴注;氟尿嘧啶750 mg·m-2...     

Tca8113和BcaCD885对口腔癌靶向隐形顺铂聚乳酸纳米粒的敏感性研究

目的：观察口腔鳞癌细胞系（Tca8113和BcaCD885）对口腔癌靶向顺铂聚乳酸聚乙二醇纳米粒（CDDP—PLA—PEG—NP，或称隐形聚乳酸纳米）的敏感性，并与顺铂（CDDP）对Tca8113和BcaCD885的抗癌活性进行对比观察。方法：用四唑盐显色法（MTr法）检测CDDP—PLA—PEG—NP和CDDP在1～8d内8个时间点对Tca8113和BcaCD885的抗癌活性，计算出2种药物在8个时间点对2种癌细胞的抑癌率和药物的半数抑癌率浓度。结果：CDDP—PLA—PEG—NP和CDDP对Tca8113和BcaCD885均有强的杀伤作用，其杀伤效应均呈时间依赖性和剂量依赖性。结论：经改型后的CDDP—PLA—PEG—NP对口腔鳞癌细胞Tca8113和BcaCD885仍有强大的杀伤作用，为以后进一步的体内实验提供了依据。     

顺铂与卡铂为主的联合化疗疗效及毒副反应的比较研究

作者近十年间行金属铂诱导化疗84例,其中顺铂 平阳霉素 长春新碱(PVP)组53例;卡铂 平阳霉素 长春新碱(CVP)组31例。治疗结果:PVP和CVP方案的近期疗效相接近,总有效率分别是86.79％和77.41％,两组差异无显著意义。毒副反应的比较表明:PVP以肾毒性、胃肠毒性和耳毒性为主,发生率分别为13.2％、79.24％和11.32％;而CVP则以骨髓毒性和肝毒性为特征,分别为38.70％和12.90％。两组分别出现的毒副反应及其并发症尚未影响诱导化疗的使用。     

口腔鳞癌顺铂诱导化疗前后端粒酶活性表达的初步报告

目的 :探讨口腔粘膜鳞状细胞癌行顺铂诱导化疗前后端粒酶活性的表达和动态改变。方法 :施行高剂量顺铂为主的ＰＶＰ诱导化疗方案 ;与化疗前后分别获取实验标本 ,离体 3 0ｍｉｎ内置 80℃冻存 ;采用ＰＣＲ -ＥＬＩＳＡ方法测定端粒酶活性。结果 :诱导化疗总有效率为 85 1 8%(2 3 / 2 7)。顺铂化疗前后的端粒酶活性阳性率有显著性差异 , (ｐ <0 0 5)。结论 :顺铂可以通过抑制端粒酶活性来抑制癌细胞的过度增殖 ,其作用机制和顺铂抗癌药理作用于ＤＮＡ交叉链有关。     

靶向siRNA干扰hTERT联合顺铂抑制Tca8113增殖的实验研究

目的：应用hTERT特异性siRNA干扰舌癌Tca8113细胞hTERT基因的表达,探讨hTERT-siRNA联合顺铂对舌癌Tca8113细胞增殖和凋亡的影响。方法：体外化学合成针对hTERT的siRNA,通过阳离子脂质体将siRNA-hTERT1转染舌癌Tca8113细胞,RT-PCR检测hTERTmRNA表达水平,Western印迹检测其蛋白表达水平,四甲基偶氮唑蓝法（MTT）及流式细胞分析法分别测定hTERT-siRNA联合顺铂处理后对舌癌Tca8113细胞增殖及凋亡的影响。数据采用SPSS13.0进行方差分析。结果：靶向hTERT的siRNA可以有效抑制舌癌Tca8113细胞株hTERT的表达,hTERT-siRNA和顺铂均可抑制Tca8113细胞增殖并诱导其一定程度的凋亡。当联合应用靶向hTERT的siRNA和顺铂时,上述作用显著加强（P〈0.05）。结论：体外化学合成的hTERTsiRNA可以有效抑制舌癌Tca8113细胞hTERT的表达,hTERT表达受抑制后,可增强顺铂作用舌癌Tca8113细胞的敏感性。     

顺铂联合术前诱导化疗治疗口腔颌面部癌肿的近期疗效

目的：研究应用以大剂量顺铂为主联合术前诱导化疗治疗口腔颌面部鳞癌和腺上皮癌的近期疗效和安全性。方法：对５６例鳞癌,采用ＶＣＰ联合化疗方案,对３６例腺上皮癌采用ＶＣ５－Ｆｕ方案。化疗结束后,按照国际通用标准,对所治疗病例进行近期疗效分析,对药物的毒副反应进行观察。结果：ＶＣＰ方案治疗５６例鳞癌的近期有效率（缓解率）为８３．９％,ＶＣ５－Ｆｕ方案治疗３６例腺上皮癌的近期有效率为６３．９％。两组的总有效     

A worldwide comparison of the management of surgical treatment of advanced oral cancer

Introduction

Microvascular surgery following tumor resection has become an important field of oral and maxillofacial surgery (OMFS). Following the results from management of T1/T2 floor-of-mouth and tongue squamous cell carcinoma (SCC) in German-speaking countries, Europe, and worldwide, this paper presents specific concepts for the management of resection and reconstruction of T3/T4 SCC of the maxillary and mandibular alveolar process and tongue.

不同剂量替尼泊苷联合化疗方案治疗口腔鳞癌的前瞻性研究

目的　前瞻性研究大、小剂量的替尼泊苷 (VM2 6)分别联合顺铂 (CDDP)和平阳霉素(PYM)对口腔颌面部鳞状细胞癌患者临床化疗效果和毒副作用。方法　共有 6 5例患者纳入研究 ,随机分为 2组 (33例和 32例 ) ,分别进行高剂量VM2 6(32 0mg)化疗方案 (PTP1)和低剂量VM2 6(15 8mg)化疗方案 (PTP2 )的治疗 ,观察、评价各自短期化疗效果和毒副反应。结果　接受高剂量VM2 6方案化疗患者 33例 ,共完成 38周期的化疗 ,化疗总有效率 (PR CR)为 81 82 % (2 7/33) ;另外32例接受低剂量VM2 6方案化疗 ,共完成 36个周期化疗 ,有效率为 81 2 5 % ,两组间化疗效果差异无显著性 (P >0 0 5 ) ;两组间患者血液毒副反应差别明显 ,高剂量VM2 6化疗组的骨髓抑制率 (1～ 4级 )达到 4 8 4 8% ,明显高于低剂量VM2 6组 (2 5 0 0 % ,P <0 0 1)。结论　鉴于低剂量VM2 6化疗方案(PTP2 )治疗口腔颌面部鳞癌的有效率及相对较轻的不良反应 ,可在口腔鳞癌临床化疗中推广应用低剂量VM2 6联合CDDP、PYM组成的化疗方案。     

Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells

Oral cancer demonstrates a strong epidemiological association with smoking, but little is known about the effect of nicotine on oral cancer cell apoptosis. Nicotine, a major component of cigarette smoke, can regulate cell proliferation and angiogenesis and suppress apoptosis induced by chemotherapeutic drugs. The main aim of this study was to investigate the effects of nicotine on apoptosis induced by cisplatin, which is commonly used to treat advanced oral cancers, in the human oral cancer cell line Tca8113. The cells were stimulated with nicotine in the presence or absence of cisplatin, and apoptosis was assayed. The results showed that nicotine inhibited apoptosis induced by cisplatin. It was also observed that survivin played a role in the inhibitory effect of nicotine on apoptosis. Depletion of survivin reduced the protective effect of nicotine against cisplatin-induced apoptosis. Akt, a physiological survivin kinase, is activated by nicotine. Treatment of Tca8113 cells with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 blocked nicotine-induced survivin expression and enhanced cell apoptosis. These studies suggest that exposure to nicotine might negatively impact on the apoptotic potential of chemotherapeutic drugs, and that survivin plays a key role in the anti-apoptotic effect of nicotine. The Akt pathway may be required for nicotine function.     

多烯紫杉醇联合顺铂和氟尿嘧啶诱导化疗对口腔鳞癌的近期疗效观察

目的：观察多烯紫杉醇联合顺铂和5-氟尿嘧啶（DCF方案）诱导化疗对口腔黏膜鳞状细胞癌的近期疗效和不良反应。方法：51例患者均经病理组织学证实为口腔黏膜鳞癌,均接受1个疗程的DCF方案（多烯紫杉醇80mg/m^2,顺铂80mg/m^2,5-氟尿嘧啶750mg/m^2×4d）化疗,并配合水化利尿、止吐及抗过敏等辅助治疗。平均21d后评定疗效,施行原发肿瘤局部扩大切除的联合根治术。化疗前详细记录病灶大小,采用WHO推荐评价实体肿瘤客观指标判定疗效,分为完全缓解、部分缓解及无效3级,总有效率为完全缓解＋部分缓解病例。结果：近期疗效中,完全缓解12例,部分缓解27例,无效12例,总有效率（CR＋PR）为76.47%（39/51）。未出现严重不良反应。结论：DCF方案对多数口腔颌面部鳞癌近期疗效明显,不良反应可以耐受,远期疗效尚待进一步研究证实。     

The results of treatment in 570 cases of oral cancer

This paper presents results of treatment in 570 cases with oral cancers. The overall 5-year survival rate was 64.5%; and 92.8%, 84.9%, 50.2% and 16.4% respectively in Stage I, II, III and IV. Five kinds of therapy have been used and discussed. The mortality rate of operation was 0.35%. The 5-year survival rates of 127 and 443 cases with and without cervical node metastases were 28.3% and 74.7% respectively. The 5-year survival rates of 81.30 and 16 cases with involvement of 1.2 and more than 3 nodes were 33.6%, 27.9% and 6.3% respectively. 46 cases recurred and operated again, their 5-year survival rate was 23%.     

Advances in the diagnosis and treatment of oral cancer.

Cancer of the oral cavity is fortunately rare in the Western world. However, rates are rising and are comparatively high in lower socioeconomic groups and in many metropolitan areas. Whenever possible, cancer of the oral cavity should be distinguished from "head and neck" cancers, because "site" is so important in the behavior of the disease. This review discusses the advantages and disadvantages of various methods of diagnosis, therapy, reconstruction, social rehabilitation, and pain control of oral cancer and of head and neck cancer.     

The methods of modern reflexotherapy in the combined treatment of patients with erosive-ulcerative processes of the oral mucosa]

The authors suggest a scheme of multiple-modality treatment of patients with erosive ulcerative processes in the buccal mucosa. This scheme was employed in the treatment of such patients and it was conducive to a sooner epithelialization of erosions and ulcers in the buccal mucosa; its analgesic effect was fairly high.